Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021)
Scholar Rock Holding's (SRRK) quarterly Current Deferred Revenue came in at $33.2 million in Q4 2021, up 76.41% year-on-year from $18.8 million in Q4 2020, and down 10.87% quarter-over-quarter from $37.2 million in Q3 2021.
Scholar Rock Holding (SRRK) Current Deferred Revenue (2017 - 2021) Analysis & Trends
Scholar Rock Holding's Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $33.2 million for Q4 2021.
- On a quarterly basis, Current Deferred Revenue rose 76.41% year-over-year to $33.2 million in Q4 2021; TTM through Dec 2021 was $33.2 million, a 76.41% increase from a year earlier, with the FY2021 full-year figure at $33.2 million, up 76.41% from the prior year.
- Current Deferred Revenue retreated to $33.2 million in Q4 2021 per SRRK's latest filing, from $37.2 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $47.3 million in Q1 2021 and bottomed at $228000.0 in Q4 2017.
- The 5-year median for Current Deferred Revenue is $20.6 million (2019), against an average of $24.5 million.
- Across the five-year window, Current Deferred Revenue jumped 8763.6% in 2018 and slumped 35.84% in 2020, its largest moves.
- Year by year, Current Deferred Revenue stood at $228000.0 in 2017, then soared by 8763.6% to $20.2 million in 2018, then advanced by 3.53% to $20.9 million in 2019, then declined by 10.07% to $18.8 million in 2020, then soared by 76.41% to $33.2 million in 2021.
- Per Business Quant, the three latest SRRK Current Deferred Revenue figures stand at $33.2 million (Q4 2021), $37.2 million (Q3 2021), and $42.7 million (Q2 2021).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Scholar Rock Holding | 6.30 Bn | 6.30 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 33.19 Mn |
| Sep 30, 2021 | 37.24 Mn |
| Jun 30, 2021 | 42.71 Mn |
| Mar 31, 2021 | 47.30 Mn |
| Dec 31, 2020 | 18.82 Mn |
| Sep 30, 2020 | 16.71 Mn |
| Jun 30, 2020 | 20.36 Mn |
| Mar 31, 2020 | 16.27 Mn |
| Dec 31, 2019 | 20.92 Mn |
| Sep 30, 2019 | 20.25 Mn |
| Jun 30, 2019 | 23.52 Mn |
| Mar 31, 2019 | 25.36 Mn |
| Dec 31, 2018 | 20.21 Mn |
| Dec 31, 2017 | 228,000.00 |